Biosimilars Poll: What is Your Opinion on Clinical Efficacy Trials?

In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.

Alvotech has received European Commission (EC) approval to begin marketing its adalimumab biosimliar AVT02, the company announced this week.

Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting.

Reverse switching occurs when patients transitioned to or initiated on a biosimilar are changed to an originator product, often because of a perceived failure in the biosimilar therapy.

When it comes to biologics, there is a constant push and pull over patent rights. Some believe this is part of a healthy market-driven economy. Others are skeptical.

With 20 biosimilar launches in the United States since 2015, opinions vary as to the strength of utilization.